Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Exagamglogene Autotemcel→

Exagamglogene Autotemcel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
CRISPR/Cas9 gene-edited autologous CD34+ haematopoietic stem-cell therapy
Mechanism of action
Autologous CD34+ cells are edited ex vivo at the erythroid-specific enhancer of BCL11A, reducing BCL11A expression in erythroid cells and increasing fetal haemoglobin (HbF) production after engraftment.
Indications / reported uses
  • Treatment of sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises, under the product-specific eligibility criteria
  • Treatment of transfusion-dependent beta-thalassaemia in patients aged 12 years and older under the applicable US and EU product authorisations

Sources: US DailyMed — CASGEVY (exagamglogene autotemcel) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

CRISPR/Cas9 gene-edited autologous CD34+ haematopoietic stem-cell therapy

Mechanism of action

Autologous CD34+ cells are edited ex vivo at the erythroid-specific enhancer of BCL11A, reducing BCL11A expression in erythroid cells and increasing fetal haemoglobin (HbF) production after engraftment.

General use cases

  • Treatment of sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises, under the product-specific eligibility criteria
  • Treatment of transfusion-dependent beta-thalassaemia in patients aged 12 years and older under the applicable US and EU product authorisations

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Exagamglogene Autotemcel Environmental Risk Assessment (ERA) (the Exagamglogene Autotemcel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.